BK virus infections Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | AlloVir, Amplyx Pharma, SL VAXiGEN

The BK virus infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“BK virus infections Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the BK virus infections Market.

Some of the key takeaways from the BK virus infections Pipeline Report:

• Companies across the globe are diligently working toward developing novel BK virus infections treatment therapies with a considerable amount of success over the years. 
• BK virus infections companies working in the treatment market are Orthogon Therapeutics, AiCuris, antibody Memo Therapeutics, SymBio Pharmaceuticals, Vera Therapeutics, AlloVir, and others, are developing therapies for the BK virus infections treatment 

• Emerging BK virus infections therapies in the different phases of clinical trials are- BK virus antiviral therapy, AIC 468, AntiBKV, Brincidofovir, MAU868, ALVR 105, and others are expected to have a significant impact on the BK virus infections market in the coming years.   
• In March 2021, In order to assess ALVR105 (Viralym-M), AlloVir started a Phase III research. This allogeneic, over-the-counter medication targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus
• In January 2021, In order to determine the safety and effectiveness of posoleucel (ALVR105,Viralym-M) in preventing clinically significant viral infections caused by CMV, EBV, HHV-6, AdV, BKV, and JCV in high-risk alloHCT recipients, AlloVir started a clinical trial
• In October 2021, Posoleucel (ViralymM, ALVR105) has been given Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) in order to treat hemorrhagic cystitis (HC) caused by viruses. The critical need for additional therapeutic alternatives for patients who have undergone hematopoietic stem cell transplantation and are at risk for contracting viral infections and hemorrhagic cystitis is acknowledged by this orphan drug designation

BK virus infections Overview

BK virus (BKV) Infection: In 1971, the BK virus was discovered in the urine of a patient receiving a kidney transplant who also had ureteric stenosis. One of the 13 known polyomaviruses is the BKvirus. Around 80–90% of persons around the world have antibodies to BKV, which indicates exposure to or previous infection with the virus. BKV infection is either asymptomatic or accompanied by a mild flu-like symptoms at first.

Get a Free Sample PDF Report to know more about BK virus infections Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/report-store/bk-virus-bkv-infection-pipeline-insight

Emerging BK virus infections Drugs Under Different Phases of Clinical Development Include:

• BK virus antiviral therapy: Orthogon Therapeutics
• AIC 468: AiCuris
• AntiBKV: antibody Memo Therapeutics
• Brincidofovir: SymBio Pharmaceuticals
• MAU868: Vera Therapeutics
• ALVR 105: AlloVir
• Viralym-M: AlloVir

Route of Administration

BK virus infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

BK virus infections Pipeline Therapeutics Assessment

• BK virus infections Assessment by Product Type
• BK virus infections By Stage and Product Type
• BK virus infections Assessment by Route of Administration
• BK virus infections By Stage and Route of Administration
• BK virus infections Assessment by Molecule Type
• BK virus infections by Stage and Molecule Type

DelveInsight’s BK virus infections Report covers around 4+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further BK virus infections product details are provided in the report. Download the BK virus infections pipeline report to learn more about the emerging BK virus infections therapies

Some of the key companies in the BK virus infections Therapeutics Market include:

Key companies developing therapies for BK virus infections are – AlloVir, Amplyx Pharmaceuticals, SL VAXiGEN, Hybridize Therapeutics, and others.

BK virus infections Pipeline Analysis:

The BK virus infections pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of BK virus infections with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for BK virus infections Treatment.
• BK virus infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• BK virus infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the BK virus infections market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about BK virus infections drugs and therapies

BK virus infections Pipeline Market Drivers

• Increase in the number of patients requiring kidney transplant worldwide, technological and medical advancements, guidelines supporting early detection and prompt diagnosis are some of the important factors that are fueling the BK virus infections Market.

BK virus infections Pipeline Market Barriers

• However, lack of effective treatment options against BK virus infection, biology of BKPyV is not completely understood, side effects associated with the current treatment options and other factors are creating obstacles in the BK virus infections Market growth.

Scope of BK virus infections Pipeline Drug Insight    

• Coverage: Global
• Key BK virus infections Companies: Orthogon Therapeutics, AiCuris, antibody Memo Therapeutics, SymBio Pharmaceuticals, Vera Therapeutics, AlloVir, and others
• Key BK virus infections Therapies: BK virus antiviral therapy, AIC 468, AntiBKV, Brincidofovir, MAU868, ALVR 105, and others
• BK virus infections Therapeutic Assessment: BK virus infections current marketed and BK virus infections emerging therapies
• BK virus infections Market Dynamics: BK virus infections market drivers and BK virus infections market barriers 

Request for Sample PDF Report for BK virus infections Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services